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Objective: To evaluate efficacy and patient preference retrospectively among intraocular 
pressure (IOP)-lowering prostamide and prostaglandin medications in a real-world clinical 
setting.
Methods: Chart review of patients with uncontrolled glaucoma or ocular hypertension seen 
at a private practice clinic (n = 55) who received bimatoprost 0.03% once daily in one eye 
and either travoprost 0.004% or latanoprost 0.005% once daily in the fellow eye. IOP was 
evaluated at the initial visit and at a follow-up visit scheduled 4–6 weeks later. At the follow-up 
visit, each patient discussed the clinical results with their physician, chose which medication 
they preferred to continue using, and were queried regarding the reason for their choice. This 
paired-eye comparison method is used routinely in clinical practice to assess clinical response 
and involve patients in decisions regarding treatment. Change in mean IOP from baseline and 
patient medication choice were the outcome measures.
Results: Bimatoprost-treated eyes (n = 52) had a mean IOP reduction of 2.7 mmHg and 
travoprost-treated eyes (n = 47) had an average decrease of 1.7 mmHg (P = 0.230). Bimatoprost 
significantly reduced mean IOP (from 19.8 mmHg at baseline to 17.1 mmHg at follow-up, 
P , 0.0001), as did travoprost (from 19.4 mmHg at baseline to 17.7 mmHg at follow-up, 
P = 0.009). Latanoprost-treated eyes were excluded from the efficacy analysis due to small 
sample size (n = 5). For continued therapy, patients chose bimatoprost over travoprost by a 
factor of 2.4 to 1. Of the 15 patients who gave a reason for their choice, 80% said their decision 
was based primarily on IOP change.
Conclusions: Bimatoprost and travoprost were efficacious in reducing IOP among patients with 
uncontrolled glaucoma and ocular hypertension. Patients preferred bimatoprost over travoprost 
when trialed in fellow eyes.
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Introduction
The prostamide bimatoprost 0.03% and the prostaglandin analogs travoprost 0.004% 
and latanoprost 0.005% are ocular hypotensive lipids, the newest class of drugs 
indicated for the lowering of intraocular pressure (IOP) in patients with glaucoma 
and ocular hypertension. These medications, administered once daily, have greater 
IOP-lowering efficacy than the beta-blocker timolol.1–3
Due to the importance of even small increments of IOP reduction for preservation 
of visual function among those with glaucoma or ocular hypertension, patients who 
are not achieving sufficiently low IOP with their current medications may benefit 
from trying a new regimen. To avoid delay in determining the effect of such changes, Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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a paired-eye comparison was used to assess the efficacy of 
prostaglandin/prostamide medications in patients who had 
uncontrolled or poorly controlled IOP.
Methods
This retrospective chart review of patients participating in 
individual, within-practice, paired-eye, open-label compari-
sons included consecutive patients seen at a private practice 
clinic between September 2002 and May 2005. Patients had 
a diagnosis of glaucoma or ocular hypertension and their IOP 
had been uncontrolled in the investigator’s clinical judgment. 
Patients had been clinically judged to be suitable candidates 
for therapy with agents of the prostamide/prostaglandin 
class. The three medications studied in this evaluation were 
bimatoprost 0.03% (Lumigan®; Allergan, Inc., Irvine, CA), 
travoprost 0.004% (Travatan®; Alcon Laboratories, Inc., 
Fort Worth, TX), and latanoprost 0.005% (Xalatan®, Pfizer, 
Inc., New York, NY). Patients were assigned to bimatoprost 
in one randomly assigned eye and another medication in 
the fellow eye. The second medication was determined at 
random, except for patients who were already using one of the 
prostaglandin/prostamide analogs. These patients switched 
to use the other two medications.
Patients included in this evaluation were examined by 
the physician and had IOP measured at the initial visit. Per 
clinical routine, patients were scheduled for a follow-up visit 
4–6 weeks later, when IOP was measured and hyperemia 
or other side effects were recorded. At the follow-up visit, 
patients were asked about the eye drops in a general way 
such as, “How are you doing with the new drops?” or “How 
are your new drops?” the physician then discussed with each 
patient the IOP findings for each eye and other aspects of 
the treatment. After conferring with the physician, patients 
determined which medication they elected to continue with 
for their ongoing glaucoma therapy. In some cases, a reason 
for the patient’s choice was noted in the chart. Patient charts 
were excluded from analysis if they had any ocular surgery 
between the initial and follow-up visit. The main outcome 
measures of the chart review were mean change in IOP from 
baseline, and percentage of patients choosing a particular 
medication for continued use. Descriptive statistics were cal-
culated. Unpaired t-tests were used to evaluate the statistical 
significance of IOP changes from baseline within a treatment 
group, and paired t-tests were performed to determine sta-
tistical significance among treatment groups in the bilateral 
comparison. P values less than 0.05 were considered statisti-
cally significant.
Results
Study population
A total of 91 patients participated in the paired-eye com-
parison. Of these, 36 were excluded from the chart review 
analysis; 17 patients’ charts were not available at the time 
of data collection, seven did not have follow-up data, four 
did not have a confirmatory diagnosis, three did not receive 
bimatoprost in one of the eyes, two had eye surgery between 
the baseline and follow-up visit, two patients did not make a 
clear choice and proceeded to use both study agents, and one 
individual only used one of the comparative agents.
Fifty patients received bimatoprost in one eye and 
travoprost in the other eye, and five patients received 
bimatoprost in one eye and latanoprost in the other eye. 
Bimatoprost was randomized to the right eye in 30 patients 
and to the left eye in 25 patients; travoprost was randomized 
to the right eye in 22 patients and to the left eye in 
28 patients; and latanoprost was randomized to the right eye 
in three patients and to the left eye in two patients. Patient 
demographics are summarized in Table 1.
Seventy-five percent of patients were taking at least one 
glaucoma medication, with 42% of patients on monotherapy 
and 35% (19/55) using two or more medications (Table 2). 
Because the majority of patients (58%, 32/55) were using 
latanoprost prior to enrolling in the study (Table 2), few 
participants were assigned to receive latanoprost during the 
study.
Table 1 Patient demographics
Patients (n) 55
Mean age, years (range) 67 (27–90)
Mean years with glaucoma 9.35
gender, n (%)
  Female 31 56.4%
  Male 24 43.6%
race, n (%)
  White/Caucasian 20 36.4%
  hispanic 11 20.0%
  Asian/Pacific Islander 10 18.2%
  Black/African American 7 12.7%
  not recorded 7 12.7%
Diagnosis, n (%)*
  Chronic open-angle glaucoma 30 54.5%
  Ocular hypertension 14 25.5%
  Low- or normal-tension glaucoma 7 10.5%
  narrow-angle glaucoma 4 7.3%
  Pigmentary 4 7.3%
  Chronic angle-closure glaucoma 2 3.6%
  Suspected glaucoma 1 1.8%
  neovascular glaucoma 1 1.8%
Note: *Some patients had a diagnosis of more than one type of glaucoma.Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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The median interval between the baseline and follow-up 
visits was 42 days (mean 72.7 days), and 10 patients had their 
follow-up visit more than 90 days after the baseline visit. 
Data were obtained for all outcome measures for all patients, 
except for three patients receiving bilateral bimatoprost or 
travoprost, for whom IOP-lowering data were not documented 
in the medical chart at the follow-up visit.
iOP reduction
Bimatoprost and travoprost significantly reduced IOP 
from baseline during the study period (Figure 1). For eyes 
receiving bimatoprost with documented IOP measurement 
at baseline and at follow-up (n = 52), IOP decreased by 
2.7 mmHg (standard deviation = 4.2 mmHg), a significant 
reduction (P , 0.0001) versus baseline. Mean (±standard 
deviation) baseline IOP for bimatoprost-treated eyes 
was 19.8 ± 4.9 mmHg (range 10–34) and dropped to 
17.1 ± 4.9 mmHg (range 19–37) at the end of the study 
period. For travoprost-treated eyes with documented IOP 
measurement at baseline and at follow-up (n = 47), IOP was 
reduced from a baseline value of 19.4 ± 4.1 mmHg (range 
12–31) to 17.7 ± 4.2 mmHg (range 9–29) at the end of the 
study period, for a decrease of 1.7 mmHg (P = 0.009 versus 
baseline). The numeric magnitude of mean IOP reduction 
with bimatoprost was larger than with travoprost (2.7 mmHg 
versus 1.7 mmHg decrease), but the difference did not reach 
statistical significance (P = 0.230).
In eyes receiving latanoprost (n = 5), mean baseline IOP 
was 19.6 ± 4.7 mmHg (range 15–26), and IOP at follow-up 
averaged 16.2 ± 2.5 mmHg (range 14–20), for a reduction 
of 3.4 ± 3.2 mmHg. This difference was not statistically 
significant (P = 0.077), probably because of the small sample 
size.
Patient choices of medication
At the follow-up visit, the physician discussed the clinical 
outcomes with each patient, and each patient chose which 
medication they would prefer to continue using. Patients who 
received bimatoprost in one eye and travoprost in the fellow 
eye chose to continue with bimatoprost over travoprost by 
a factor of 2.4 to 1 (Figure 2). Nearly seven of 10 patients 
chose bimatoprost (68%, 34/50), 28% of patients (14/50) 
chose travoprost, and 4% (2/50) chose neither. The two 
patients who chose neither option had used latanoprost 
Table 2 glaucoma medications used prior to study
n %
number of medications
 0 13 23.7%
 1 23 41.8%
 2 11 20.0%
 3 7 12.7%
 4 1 1.8%
Previous medications*
  Latanoprost 32 58.2%
  Brimonidine/adrenergic agonist 11 20.0%
  Dorzolamide/timolol combination 10 18.2%
  Timolol/beta-blocker 10 18.2%
  Dorzolamide/carbonic anhydrase inhibitor 5 9.1%
  Carbachol 1 1.8%
  Travoprost 1 1.8%
  none 13 23.6%
Note: *Some patients were receiving more than one medication prior to study 
therapy.
I
O
P
,
 
m
e
a
n
 
r
e
d
u
c
t
i
o
n
f
r
o
m
 
b
a
s
e
l
i
n
e
,
 
m
m
 
H
g
0.0
−1.0
−2.0
−3.0
−2.7
−1.7
Bimatoprost
(n = 52)
Travoprost
(n = 47)
*P < 0.0001 vs baseline
**P = 0.009 vs baseline *
**
Figure 1 Change in mean iOP from baseline. iOP reduction seen over 4–6 weeks of 
QD treatment. Baseline mean iOP: bimatoprost 19.8 mmhg; travoprost 19.4 mmhg. 
Follow-up iOP: bimatoprost 17.1 mmhg; travoprost 17.2 mmhg. P = 0.230 for 
bimatoprost versus travoprost change bilateral paired-eye analysis of change in iOP 
from baseline. 
Abbreviation: iOP, intraocular pressure.
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Figure 2 glaucoma medications chosen by patients. After 4–6 weeks of bilateral 
glaucoma therapy, patients chose which medication they would prefer to continue 
using  as  their  ongoing  regimen.  Data  shown  are  for  patients  who  received 
bimatoprost in one eye and travoprost in the fellow eye.Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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prior to the study, and elected to continue with it afterwards. 
Among the five patients who received bilateral bimatoprost 
or latanoprost, three chose to continue with bimatoprost, 
one chose latanoprost, and one chose neither (this patient 
had been using travoprost prior to the study and chose to 
continue with it).
Table 3 shows the primary factor that patients stated 
influenced their choice of medication. Among the 15 patients 
who stated a reason, most (80%, 12/15) cited improvement 
in IOP as the primary factor in their decision. A majority of 
these patients (83%, 10/12) preferred bimatoprost over the 
agent they had used in the fellow eye.
Other reasons offered by patients for determination of 
medication choice were “pressure change plus better side 
effect profile”, “convenience”, and “price”, cited by one 
patient each (medications chosen were travoprost, and 
latanoprost, respectively). No patients cited “side effect 
profile” as a primary influence on their medication choice. 
Looking at the entire study population analyzed (n = 55), 
hyperemia was reported by eight patients, with six report-
ing hyperemia in both eyes, one reporting hyperemia in the 
bimatoprost-treated eye only, and one reporting hyperemia 
in the travoprost-treated eye only.
Discussion
Patients with glaucoma or ocular hypertension who did not 
have sufficient IOP control with their current medication 
regimens instilled bimatoprost in one eye and either 
travoprost or latanoprost in the other eye. Significant IOP 
reductions were observed for bimatoprost- and travoprost-
treated eyes, consistent with published results.1–4
Relatively few studies have directly compared the 
efficacy of prostaglandin/prostamide glaucoma therapies. In 
a meta-analysis of all head-to-head randomized, investigator-
masked direct comparisons of latanoprost, bimatoprost, and 
travoprost, bimatoprost was more efficacious at lowering 
IOP than travoprost in the two direct comparisons identified 
(involving 150 patients), and bimatoprost was found to 
be more efficacious than latanoprost in six head-to-head 
studies identified (involving 460 patients).4 Our study may 
not have been adequately powered to detect statistically 
significant differences among therapies. However, for the 
two therapies where we detected a significant IOP decline 
from baseline (bimatoprost and travoprost), bimatoprost 
showed qualitatively greater IOP reduction than travoprost, 
consistent with a report by Holmstrom et al.4
An important limitation of this assessment was the fact 
that relatively few eyes were randomized to receive latano-
prost. Because nearly 60% of study participants had been 
receiving latanoprost prior to the study, only five patients 
received latanoprost as one of the comparators. Therefore, for 
these patients, the bilateral comparison was limited to travo-
prost and bimatoprost. Because of the small sample size, the 
results with latanoprost may be difficult to generalize. Use of 
a larger study population, or employment of a multiple-study 
site design in future trials may result in a patient population 
that is more evenly distributed among the cohorts.
It should be noted that our results are consistent 
with those of a large-scale “real-world” study, in which 
more than 15,000 glaucoma patients on latanoprost were 
switched to bimatoprost in a nationwide health maintenance 
organization.5 In that study, patients switching to bimatoprost 
experienced statistically significant IOP reduction, and few 
reverted to their previous medication.5
Nonadherence to glaucoma treatment regimens is a sig-
nificant problem, in large part because glaucoma is chronic, 
progressive, and symptom-free in its early stages.6–8 In the 
treatment practice described in this report, patients chose 
which medication to continue using after consulting with 
the physician. The patient–physician partnership in medi-
cal decision-making is increasing as patients become more 
empowered through consumerism and access to independent 
information resources, such as the Internet.9 A majority of 
patients in this study who gave a reason for their choice cited 
IOP-lowering efficacy, as opposed to side effects or other 
aspects of the medication immediately perceptible to the 
patient. Our results, while preliminary, raise the intriguing 
question of whether patients who are involved in their medical 
decision-making might also have improved adherence to their 
glaucoma regimens. Further study may be warranted.
Conclusion
After direct comparisons between glaucoma drugs trialed 
in each eye, patients preferred bimatoprost over travoprost 
by a factor of 2.4 to 1. Today’s therapeutic armamentarium 
offers multiple choices for achieving target IOP. Physicians 
Table 3 Factors in patients’ choice of glaucoma medication
reasons not stated 40 72.7%
reasons stated 15 27.3%
Specific reasons (n = 15)
  iOP improvement 12 80.0%
  Side effect profile 0 0.0%
  IOP improvement and better side effect profile 1 6.7%
  Convenience 1 6.7%
  Price 1 6.7%
Abbreviation: iOP, intraocular pressure.Clinical Ophthalmology
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may wish to consider a simple bilateral trial such as ours for 
their glaucoma patients who are not achieving adequate IOP 
control with their current medication regimens.
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